Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DBT-01
- Development stage
- Preclinical
- Lead developer
- Discovery Biotech
01
Overview
DBT-01 is an investigational therapeutic candidate being developed by Discovery Biotech to address cancer therapy resistance. It is the lead program in the company's pipeline, which focuses on overcoming resistance mechanisms such as genetic mutations, alterations in drug processing, and changes within the tumor microenvironment. As of April 2024, DBT-01 is in the Investigational New Drug (IND) stage of development. While the specific molecular target and modality have not been publicly disclosed, the program is part of a broader effort to develop products that combat resistance in various oncology indications.
Beyond the preview
Go deeper on DBT-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DBT-01.